Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303)
Journal
-
- Frontiers in Oncology
-
Frontiers in Oncology 9 132-, 2019-03-11
Frontiers Media SA
- Tweet
Details 詳細情報について
-
- CRID
- 1362262945769019776
-
- ISSN
- 2234943X
-
- Data Source
-
- Crossref